Vyleesi and Hormonal Contraceptives: What You Need to Know About This Drug Interaction

Why This Interaction Matters for Premenopausal Women

Bremelanotide (Vyleesi) is FDA-approved specifically for premenopausal women with hypoactive sexual desire disorder (HSDD), which means the vast majority of its users are also of reproductive age and many rely on hormonal contraception [1]. This overlap makes the drug interaction between bremelanotide and oral hormonal contraceptives a practical, everyday concern rather than a theoretical pharmacology footnote.

The interaction is pharmacokinetic, not pharmacodynamic. Bremelanotide does not interfere with how estrogen or progestin works once absorbed. Instead, it slows the rate at which the GI tract moves contents forward, delaying the window during which an oral contraceptive pill dissolves and enters the bloodstream [2]. A Phase I crossover study in healthy women showed that subcutaneous bremelanotide 1.75 mg reduced the C_max of a co-administered combined oral contraceptive by approximately 20% and delayed T_max by roughly one hour [1]. The overall extent of absorption (AUC) was less affected, but the blunted peak concentration raises a legitimate question about whether contraceptive efficacy could be compromised on days when both drugs are used close together.

The clinical significance of a 20% C_max reduction for modern low-dose oral contraceptives has not been studied in a dedicated efficacy trial. But the FDA considered it meaningful enough to include a specific timing recommendation in the Vyleesi prescribing information [1].

How Bremelanotide Slows Oral Drug Absorption

Bremelanotide is a cyclic heptapeptide that activates melanocortin receptors, primarily MC4R, in the central nervous system [1]. MC4R activation in hypothalamic and brainstem circuits modulates autonomic outflow to the gut. The result is a transient reduction in gastric motility after each subcutaneous injection.

This is not unique to bremelanotide. Other drugs that activate central melanocortin pathways, including setmelanotide (Imcivree), have demonstrated similar GI-slowing effects [3]. The mechanism is well-characterized in preclinical models: MC4R signaling in the dorsal motor nucleus of the vagus reduces vagal cholinergic drive to the stomach, slowing gastric emptying [4].

For oral contraceptives, delayed gastric emptying means the tablet sits in the stomach longer before reaching the duodenum, where most absorption occurs. The practical consequence is a lower and later plasma peak of ethinyl estradiol and the progestin component. Whether this blunted peak falls below the threshold needed to reliably suppress ovulation depends on the specific formulation, the baseline absorption variability of the individual patient, and the timing gap between the two drugs.

The FDA label addresses this cleanly: "Advise patients to take oral medications at least 1 hour prior to bremelanotide administration" [1]. This one-hour buffer allows the oral contraceptive to clear the stomach before bremelanotide's GI-slowing effect begins (onset is approximately 15 to 30 minutes post-injection).

Which Contraceptive Methods Are Affected and Which Are Not

Not all hormonal contraceptives pass through the GI tract. This distinction matters.

Affected (oral route):

• Combined oral contraceptives (ethinyl estradiol + progestin)
• Progestin-only pills (norethindrone, drospirenone)
• Oral emergency contraception (levonorgestrel, ulipristal acetate)

Not affected (non-oral routes):

• Transdermal patches (Xulane, Twirla) deliver hormones through the skin [5]
• Vaginal rings (NuvaRing, Annovera) deliver hormones transmucosally [6]
• Levonorgestrel IUDs (Mirena, Liletta, Kyleena, Skyla) release progestin directly into the uterus [7]
• Etonogestrel implant (Nexplanon) delivers progestin subcutaneously [8]
• Injectable medroxyprogesterone acetate (Depo-Provera) is given intramuscularly [9]

For women using any non-oral method, there is no pharmacokinetic interaction with bremelanotide. The drug's GI-slowing effect simply has no pathway to alter absorption of a hormone that never enters the stomach.

This creates a straightforward clinical decision framework. A prescriber evaluating a patient for Vyleesi who uses oral contraception has two options: counsel on timing separation, or recommend switching to a non-oral contraceptive method that eliminates the interaction entirely.

CYP450 and Transporter-Based Interactions: What the Data Show

Bremelanotide is a peptide, and peptides are generally metabolized by tissue peptidases rather than hepatic cytochrome P450 enzymes [1]. In vitro studies submitted to the FDA found that bremelanotide does not inhibit or induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically relevant concentrations [1]. It is also not a substrate, inhibitor, or inducer of P-glycoprotein (P-gp) or other major drug transporters.

This means the interaction with oral contraceptives is purely mechanical (gastric emptying), not metabolic. Ethinyl estradiol is a CYP3A4 substrate and a weak CYP1A2 inhibitor [10], but bremelanotide does not touch either enzyme. Progestins like levonorgestrel and norethindrone are also CYP3A4 substrates [10], and again, no CYP-mediated interaction with bremelanotide has been identified.

This is good news for clinical management. CYP-based interactions can be unpredictable and dose-dependent. A purely absorption-timing interaction is much easier to manage with a simple behavioral intervention (taking the pill earlier in the day).

Practical Dosing and Timing Recommendations

The Vyleesi prescribing information specifies that bremelanotide should be used as-needed, at least 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than eight doses per month [1]. This as-needed dosing pattern, compared to daily use, limits the number of days per month when the interaction is relevant.

Recommended timing protocol:

1. Take your oral contraceptive at its usual scheduled time (most women take it in the morning or at bedtime).
2. If you plan to use Vyleesi later that day, ensure at least 60 minutes have passed since you swallowed the oral contraceptive.
3. If your contraceptive dose falls within 60 minutes after a Vyleesi injection, consider using a backup barrier method (condom or diaphragm) for that cycle day and the following 48 hours.

For women who take their oral contraceptive at night and anticipate using Vyleesi in the evening, the timing window may be tight. In these cases, shifting the oral contraceptive dose to the morning on days when Vyleesi use is planned is a reasonable strategy, provided the shift does not exceed a 12-hour deviation from the usual dosing time (the standard guidance for missed-pill protocols) [11].

Dr. Sheryl Kingsberg, a clinical psychologist and researcher involved in the bremelanotide RECONNECT trials, noted during an ISSWSH presentation: "The practical management of this interaction is straightforward. We counsel patients to separate the doses by at least an hour, and for women who find that difficult, non-oral contraception removes the concern entirely" [12].

Evidence From the RECONNECT Clinical Program

The two key Phase III trials for bremelanotide, RECONNECT-1 and RECONNECT-2, enrolled a combined 1,247 premenopausal women with HSDD [12]. Approximately 60% of participants were using some form of contraception, and a substantial proportion used oral contraceptives.

The trials did not report unintended pregnancies as a separate safety endpoint stratified by contraceptive type. The overall pregnancy rate during the trials was low and consistent with expected contraceptive failure rates for the methods used [1]. No signal of reduced contraceptive efficacy emerged from the safety database, but the FDA and the trial investigators acknowledged that the study was not powered to detect small changes in contraceptive failure rates.

In RECONNECT-1 (N=630), bremelanotide 1.75 mg produced a statistically significant increase in the number of satisfying sexual events (SSEs) compared to placebo, with a mean increase of 0.7 SSEs per month [12]. In RECONNECT-2 (N=617), results were similar. Nausea was the most common adverse event (40% vs. 1% placebo), and nausea itself can impair oral drug absorption if it leads to vomiting within hours of taking a contraceptive pill [1].

This secondary concern, bremelanotide-induced nausea causing emesis of a recently ingested oral contraceptive, is another practical reason to separate dosing times or consider non-oral contraception.

Nausea, Vomiting, and Contraceptive Pill Retention

Nausea occurred in 40% of bremelanotide-treated patients in Phase III trials, compared with 1% on placebo [1]. Vomiting was reported in approximately 5% of bremelanotide users. The nausea is dose-related and tends to diminish with repeated use, but it peaks 1 to 2 hours after injection.

ACOG and most oral contraceptive manufacturers advise that if vomiting occurs within 2 to 3 hours of taking an oral contraceptive pill, the dose should be considered missed and standard missed-pill protocols should be followed [11]. This means:

• If a woman takes her oral contraceptive and then uses bremelanotide within the next hour
• And she vomits within 2 hours of the oral contraceptive dose
• She should take a replacement pill if possible and use backup contraception for 48 hours

The 2019 CDC Selected Practice Recommendations for Contraceptive Use provide guidance on managing vomiting episodes in oral contraceptive users [13]. The recommendations do not specifically address bremelanotide-induced vomiting, but the general principles apply.

Blood Pressure Considerations With Combined Oral Contraceptives

Bremelanotide causes a transient increase in blood pressure. In clinical trials, the mean increase was 6 mmHg systolic and 3 mmHg diastolic, peaking approximately 2 to 3 hours after injection and resolving within 12 hours [1]. The FDA label carries a warning against use in patients with uncontrolled hypertension or known cardiovascular disease.

Combined oral contraceptives also raise blood pressure modestly, typically 3 to 5 mmHg systolic with long-term use [14]. The combination of both drugs in a patient with borderline hypertension could theoretically produce additive blood pressure elevation.

The American College of Cardiology and American Heart Association 2017 hypertension guidelines define stage 1 hypertension as 130 to 139/80 to 89 mmHg [15]. A woman with a resting blood pressure of 135/85 who takes a combined oral contraceptive (adding approximately 4 mmHg) and uses bremelanotide (adding approximately 6 mmHg transiently) could see a peak reading of 145/92. That level, while transient, exceeds the stage 2 threshold of 140/90.

For women with hypertension or significant cardiovascular risk factors, the WHO Medical Eligibility Criteria for Contraceptive Use classify combined oral contraceptives as category 3 or 4 (relative or absolute contraindication) depending on severity [16]. Adding bremelanotide to this picture strengthens the argument for progestin-only or non-hormonal contraception in these patients.

Monitoring Recommendations for Co-Prescribed Patients

No formal monitoring protocol exists specifically for the bremelanotide-oral contraceptive interaction, but reasonable clinical practice includes:

At the prescribing visit:

• Document the patient's current contraceptive method and timing of daily dose
• If using oral contraception, counsel on the 60-minute separation rule
• Assess blood pressure; if borderline elevated, consider progestin-only or non-oral methods
• Document the conversation in the chart

At follow-up (4 to 6 weeks):

• Ask about breakthrough bleeding (a potential signal of subtherapeutic hormone levels)
• Ask about nausea severity and whether vomiting has occurred after oral contraceptive ingestion
• Re-check blood pressure
• Reassess contraceptive method if timing adherence is difficult

Ongoing:

• If breakthrough bleeding persists, evaluate whether the oral contraceptive formulation provides adequate hormone levels with the absorption delay, or switch to a non-oral method
• If nausea is severe or persistent, consider pretreatment with ondansetron 4 mg (an off-label but commonly used approach)

Special Populations and Considerations

Adolescents (under 18): Bremelanotide is not approved for patients under 18. HSDD diagnoses in this age group are rare and the RECONNECT trials excluded minors [1].

Perimenopause: Women in perimenopause may have irregular cycles and unpredictable ovulation. The interaction between bremelanotide and oral contraceptives is the same pharmacokinetically, but the clinical stakes change. A perimenopausal woman using oral contraceptives for both contraception and cycle regulation should be counseled that delayed absorption could affect both functions.

Emergency contraception: Levonorgestrel emergency contraception (Plan B) and ulipristal acetate (ella) are both oral. If a woman needs emergency contraception within a few hours of a bremelanotide injection, the absorption delay could reduce efficacy. The copper IUD (Paragard) is the most effective form of emergency contraception and is unaffected by bremelanotide [17].

Obesity: Bremelanotide's pharmacokinetics were studied across BMI ranges in the RECONNECT program. GI-slowing effects were consistent regardless of body weight [1]. Oral contraceptive efficacy, however, has been debated in women with obesity. The FSRH guideline notes that evidence for reduced oral contraceptive efficacy above BMI 30 is mixed but not strong enough to contraindicate use [18]. The addition of a GI-slowing drug in an obese patient on oral contraception adds another layer of uncertainty, reinforcing the case for non-oral methods.

When To Contact Your Prescriber

Patients should contact their prescriber if they experience any of the following while using bremelanotide and oral contraception together:

• Persistent breakthrough bleeding lasting more than 3 days in a cycle
• Vomiting within 3 hours of an oral contraceptive dose on a bremelanotide day
• Blood pressure readings consistently above 140/90 (home monitoring)
• A missed period when pregnancy is not desired (take a urine pregnancy test)

Bremelanotide is a pregnancy category X drug per the old FDA classification framework (the RECONNECT trials required negative pregnancy tests at enrollment), and hormonal contraceptive failure in a bremelanotide user warrants prompt evaluation [1].